Monday, 3 December, 2007 - 11:52
Visiomed takes major step into US market
Nedlands-based Visiomed Group Ltd has secured United States FDA clearance for its redesigned and improved 'Funhaler' paediatric asthma incentive spacer.
William Dolphin was appointed to the Avita Medical board on 5 March 2008 and then appointed as CEO July, serving until late 2013. He was previously CEO of Visiomed Group Limited. Dr Dolphin holds a PhD in biophysics obtained from Boston University in 1989. He held appointments as professor in the Departments of Bio-medical Engineering and Biology at Boston
University and served as president and chief technology officer of a US-based contract research and development company. Dr Dolphin was subsequently the president, CEO and chairman of a US medical device company. In 2003 he relocated to New Zealand and was CEO of a technology joint venture. Dr Dolphin has served as a director of numerous companies in the US, NZ and Australia, is the author of more than 60 peer-reviewed scientific articles, holds five US and international patents and was twice recipient of the National Research Service Award from the US National Institutes of Health.
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
555th | Parkway Corporate">Parkway Corporate | 19.97% | 14.84% |
556th | Chorus Limited">Chorus Limited | 19.87% | 12.16% |
557th | Avita Medical">Avita Medical | 19.74% | -20.62% |
558th | Whitefield">Whitefield | 19.69% | 6.15% |
559th | CleanSpace Holdings">CleanSpace Holdings | 19.68% | 0% |
Nedlands-based Visiomed Group Ltd has secured United States FDA clearance for its redesigned and improved 'Funhaler' paediatric asthma incentive spacer.
Dalton Gooding has agreed to stand down as chairman of biotech company Avita Medical but shareholders today supported the re-election of Professor Fiona Wood as a director.
FEATURE: It has been a difficult year for many of WA’s listed entities, but investors are backing the performance of most of the state’s top executives.
William Dolphin has agreed to step down as chief executive of biotech company Avita Medical, and Dalton Gooding has resigned after announcing his intention to do so at the company's annual general meeting in November.
Biotech company Avita Medical has appointed a new chairman after shareholder outrage against the company's remuneration report last year claimed the scalp of former chairman Dalton Gooding.
WA biotechs are drowning in a sea of red as yet more negative results are reported.
Perth biotechnology firm Avita Medical has announced major changes to a clinical trial in the US it hopes will improve shareholder confidence.
Shares in Avita Medical have hit a 2014 low following the company’s announcement efforts to commercialise in the UK have hit a snag.
Position | Company | Year | Company's current rank |
---|---|---|---|
Managing Director
|
2008 - 2013 |
Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
---|---|---|---|---|---|---|
2012-11-05 | Bought | 125,000 | $0.12 | $15,000 | Other | |
2011-06-24 | Bought | 1,300,000 | $0.10 | $130,000 | Other | |
2010-11-01 | Bought | 85,000 | $0.11 | $8,925 | On-market trade | |
2010-10-14 | Bought | 90,000 | $0.11 | $9,900 | On-market trade | |
2010-07-12 | Bought | 55,000 | $0.11 | $6,050 | On-market trade |